Pulmonary sarcomatoid carcinoma: University of Cincinnati experience

Nagla Abdel Karim; James Schuster; Ihab Eldessouki; Ola Gaber; Tariq Namad; Jiang Wang; Changchun Xie; John C. Morris

doi:10.18632/oncotarget.23468

Pulmonary sarcomatoid carcinoma: University of Cincinnati experience

Nagla Abdel Karim, James Schuster, Ihab Eldessouki, Ola Gaber, Tariq Namad, Jiang Wang, Changchun Xie, John C. Morris

Pulmonary Disease

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

Objectives: To review the outcomes of treatment in patients with pulmonary sarcomatoid carcinoma (PSC) treated at the University of Cincinnati Medical Center (UCMC). Results: There was no significant difference in survival of patients treated with chemotherapy alone (median, 256 days) compared to patients not undergoing treatment (median, 205.5 days). Patients who underwent surgery and adjuvant chemotherapy showed a trend in improvement of survival (median, 457.6 days). Patients requiring only surgery had the longest OS of 713.5 days. Conclusions: Systemic chemotherapy alone did not improve survival in patients with PSC. Surgery provides the greatest overall survival benefit and adjuvant chemotherapy may also improve survival. Methods: From 2000 to 2014, twenty-five patients with pathologically confirmed PSC were treated at UCMC. The outcomes were retrospectively analyzed by treatment with overall survival (OS) as the endpoint.

Original language	English (US)
Pages (from-to)	4102-4108
Number of pages	7
Journal	Oncotarget
Volume	9
Issue number	3
DOIs	https://doi.org/10.18632/oncotarget.23468
State	Published - 2018

Keywords

Chemotherapy
Lung cancer
Non-small cell lung cancer
Sarcomatoid

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.18632/oncotarget.23468

Cite this

@article{6a273e4d99364fd59332a53e210c1cc4,

title = "Pulmonary sarcomatoid carcinoma: University of Cincinnati experience",

abstract = "Objectives: To review the outcomes of treatment in patients with pulmonary sarcomatoid carcinoma (PSC) treated at the University of Cincinnati Medical Center (UCMC). Results: There was no significant difference in survival of patients treated with chemotherapy alone (median, 256 days) compared to patients not undergoing treatment (median, 205.5 days). Patients who underwent surgery and adjuvant chemotherapy showed a trend in improvement of survival (median, 457.6 days). Patients requiring only surgery had the longest OS of 713.5 days. Conclusions: Systemic chemotherapy alone did not improve survival in patients with PSC. Surgery provides the greatest overall survival benefit and adjuvant chemotherapy may also improve survival. Methods: From 2000 to 2014, twenty-five patients with pathologically confirmed PSC were treated at UCMC. The outcomes were retrospectively analyzed by treatment with overall survival (OS) as the endpoint.",

keywords = "Chemotherapy, Lung cancer, Non-small cell lung cancer, Sarcomatoid",

author = "Karim, {Nagla Abdel} and James Schuster and Ihab Eldessouki and Ola Gaber and Tariq Namad and Jiang Wang and Changchun Xie and Morris, {John C.}",

note = "Publisher Copyright: {\textcopyright} Abdel Karim et al.",

year = "2018",

doi = "10.18632/oncotarget.23468",

language = "English (US)",

volume = "9",

pages = "4102--4108",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals",

number = "3",

}

TY - JOUR

T1 - Pulmonary sarcomatoid carcinoma

T2 - University of Cincinnati experience

AU - Karim, Nagla Abdel

AU - Schuster, James

AU - Eldessouki, Ihab

AU - Gaber, Ola

AU - Namad, Tariq

AU - Wang, Jiang

AU - Xie, Changchun

AU - Morris, John C.

N1 - Publisher Copyright: © Abdel Karim et al.

PY - 2018

Y1 - 2018

N2 - Objectives: To review the outcomes of treatment in patients with pulmonary sarcomatoid carcinoma (PSC) treated at the University of Cincinnati Medical Center (UCMC). Results: There was no significant difference in survival of patients treated with chemotherapy alone (median, 256 days) compared to patients not undergoing treatment (median, 205.5 days). Patients who underwent surgery and adjuvant chemotherapy showed a trend in improvement of survival (median, 457.6 days). Patients requiring only surgery had the longest OS of 713.5 days. Conclusions: Systemic chemotherapy alone did not improve survival in patients with PSC. Surgery provides the greatest overall survival benefit and adjuvant chemotherapy may also improve survival. Methods: From 2000 to 2014, twenty-five patients with pathologically confirmed PSC were treated at UCMC. The outcomes were retrospectively analyzed by treatment with overall survival (OS) as the endpoint.

AB - Objectives: To review the outcomes of treatment in patients with pulmonary sarcomatoid carcinoma (PSC) treated at the University of Cincinnati Medical Center (UCMC). Results: There was no significant difference in survival of patients treated with chemotherapy alone (median, 256 days) compared to patients not undergoing treatment (median, 205.5 days). Patients who underwent surgery and adjuvant chemotherapy showed a trend in improvement of survival (median, 457.6 days). Patients requiring only surgery had the longest OS of 713.5 days. Conclusions: Systemic chemotherapy alone did not improve survival in patients with PSC. Surgery provides the greatest overall survival benefit and adjuvant chemotherapy may also improve survival. Methods: From 2000 to 2014, twenty-five patients with pathologically confirmed PSC were treated at UCMC. The outcomes were retrospectively analyzed by treatment with overall survival (OS) as the endpoint.

KW - Chemotherapy

KW - Lung cancer

KW - Non-small cell lung cancer

KW - Sarcomatoid

UR - http://www.scopus.com/inward/record.url?scp=85040177632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040177632&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.23468

DO - 10.18632/oncotarget.23468

M3 - Article

AN - SCOPUS:85040177632

SN - 1949-2553

VL - 9

SP - 4102

EP - 4108

JO - Oncotarget

JF - Oncotarget

IS - 3

ER -

Pulmonary sarcomatoid carcinoma: University of Cincinnati experience

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this